Medical Device | June 04, 2026
HeartBeam study shows pocket-sized ECG device can predict heart attack risk
Highlights potential for at-home heart attack risk assessment, offering a new approach to reducing treatment delays
Highlights potential for at-home heart attack risk assessment, offering a new approach to reducing treatment delays
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease
POSEIDON is among the largest global datasets to quantify this residual inflammatory burden
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm
Africa CDC activates continental coordination measures; consultations underway on possible Public Health Emergency declaration
Marking World Asthma Day 2026, doctors sounded the alarm over a steady surge in respiratory illnesses
The renewal covers two versions of the IQOS device and three HEETS tobacco variants
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
Subscribe To Our Newsletter & Stay Updated
